-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Should You Be Adding Grand Pharmaceutical Group (HKG:512) To Your Watchlist Today?
Should You Be Adding Grand Pharmaceutical Group (HKG:512) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
In contrast to all that, many investors prefer to focus on companies like Grand Pharmaceutical Group (HKG:512), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
See our latest analysis for Grand Pharmaceutical Group
Grand Pharmaceutical Group's Earnings Per Share Are Growing
If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. That means EPS growth is considered a real positive by most successful long-term investors. Shareholders will be happy to know that Grand Pharmaceutical Group's EPS has grown 35% each year, compound, over three years. If the company can sustain that sort of growth, we'd expect shareholders to come away satisfied.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. On the revenue front, Grand Pharmaceutical Group has done well over the past year, growing revenue by 35% to HK$8.6b but EBIT margin figures were less stellar, seeing a decline over the last 12 months. So if EBIT margins can stabilize, this top-line growth should pay off for shareholders.
You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.
SEHK:512 Earnings and Revenue History August 9th 2022The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Grand Pharmaceutical Group's future EPS 100% free.
Are Grand Pharmaceutical Group Insiders Aligned With All Shareholders?
Insider interest in a company always sparks a bit of intrigue and many investors are on the lookout for companies where insiders are putting their money where their mouth is. This view is based on the possibility that stock purchases signal bullishness on behalf of the buyer. Of course, we can never be sure what insiders are thinking, we can only judge their actions.
Belief in the company remains high for insiders as there hasn't been a single share sold by the management or company board members. But the real excitement comes from the HK$711k that Executive Director Zhanqi Niu spent buying shares (at an average price of about HK$4.10). Strong buying like that could be a sign of opportunity.
On top of the insider buying, we can also see that Grand Pharmaceutical Group insiders own a large chunk of the company. In fact, they own 49% of the shares, making insiders a very influential shareholder group. Shareholders and speculators should be reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. This insider holding amounts to That level of investment from insiders is nothing to sneeze at.
Should You Add Grand Pharmaceutical Group To Your Watchlist?
If you believe that share price follows earnings per share you should definitely be delving further into Grand Pharmaceutical Group's strong EPS growth. Better still, insiders own a large chunk of the company and one has even been buying more shares. So it's fair to say that this stock may well deserve a spot on your watchlist. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Grand Pharmaceutical Group that you should be aware of.
Keen growth investors love to see insider buying. Thankfully, Grand Pharmaceutical Group isn't the only one. You can see a a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对于初学者来说,收购一家向投资者讲述一个好故事的公司似乎是一个好主意(也是一个令人兴奋的前景),即使它目前没有收入和利润的记录。但正如彼得·林奇在华尔街上的一位“远投几乎永远不会有回报。”一家亏损的公司还没有用盈利来证明自己,最终外部资本的流入可能会枯竭。
与此形成鲜明对比的是,许多投资者更倾向于关注像大药业集团(HKG:512),不仅有收入,而且有利润。现在,这并不是说该公司提供了最好的投资机会,但盈利能力是商业成功的关键组成部分。
查看我们对大药业集团的最新分析
大药业集团每股收益不断增长
如果一家公司能够在足够长的时间内保持每股收益(EPS)的增长,其股价最终应该会随之而来。这意味着,大多数成功的长期投资者认为,每股收益的增长是一个真正的积极因素。股东们会很高兴地知道,大药业集团的每股收益在过去三年里以每年35%的复合增长率增长。如果公司能够保持这样的增长,我们预计股东们会满意地离开。
仔细考虑收入增长和息税前利润(EBIT)利润率有助于了解最近利润增长的可持续性。在收入方面,大药业集团在过去一年中表现良好,收入增长35%,至86亿港元,但息税前利润数据没有那么亮眼,过去12个月出现下降。因此,如果息税前利润能够企稳,这种营收增长应该会为股东带来回报。
你可以在下面的图表中看到该公司的收入和收益增长趋势。点击图表查看确切的数字。
联交所:512盈利及收入历史2022年8月9日作为投资者,诀窍在于找到符合以下条件的公司要去在未来有好的表现,而不仅仅是在过去。虽然水晶球不存在,但你可以查看我们对大药业集团未来每股收益100%免费的共识分析师预测的可视化。
大药业集团内部人士是否与所有股东一致?
内部人对一家公司的兴趣总是会引发一些阴谋,许多投资者都在寻找内部人把钱放在嘴边的公司。这种观点是基于这样一种可能性,即购买股票代表买家发出看涨信号。当然,我们永远无法确定内部人士在想什么,我们只能判断他们的行为。
内部人士对该公司的信心仍然很高,因为管理层或董事会成员没有出售过一股股票。但真正令人兴奋的是董事高管牛占奇斥资71.1万港元买入股票(平均价约4.10港元)。像这样的强劲买入可能是机会的迹象。
除了内幕收购,我们还可以看到,大药业集团内部人士持有该公司很大一部分股份。事实上,他们拥有49%的股份,使内部人士成为一个非常有影响力的股东群体。股东和投机者应该对这种调整感到放心,因为它表明企业的运营将为股东的利益服务。这种内部人持股相当于来自内部人的投资水平,不容忽视。
你应该将大药业集团添加到你的观察名单中吗?
如果你相信股价跟随每股收益,你肯定应该进一步研究大药业集团强劲的每股收益增长。更好的是,内部人士拥有该公司的很大一部分股份,其中一人甚至一直在购买更多股票。因此,公平地说,这只股票很可能值得在你的观察名单上占有一席之地。别忘了,可能还会有风险。例如,我们已经确定大药业集团的1个警告标志这一点你应该知道。
热衷于增长的投资者喜欢看到内幕收购。值得庆幸的是,大药业集团并不是唯一一家。你可以在这里看到它们的免费列表。
请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧